ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,164.40
      0.00%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      85.405
      0.35%
      Bitcoin
      62,765.50
      0.26%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Esperion Therapeutics Inc (ESPR)

      7. Esperion Therapeutics Inc (ESPR) News

      ESPR

      Esperion Therapeutics (ESPR)

      Esperion Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ESPR
      DateTimeSourceHeadlineSymbolCompany
      02/16/20244:30PMGlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
      02/14/20242:14PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
      02/14/202410:50AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
      02/14/20248:42AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
      02/14/20246:11AMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ESPREsperion Therapeutics Inc
      02/13/20248:00AMGlobeNewswire Inc.Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27NASDAQ:ESPREsperion Therapeutics Inc
      02/01/20242:00PMGlobeNewswire Inc.RFK, Esperion Therapeutics Announce 2024 Promotional ScheduleNASDAQ:ESPREsperion Therapeutics Inc
      01/23/20244:00PMGlobeNewswire Inc.Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesNASDAQ:ESPREsperion Therapeutics Inc
      01/22/20246:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
      01/22/20246:04AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ESPREsperion Therapeutics Inc
      01/18/20249:15PMGlobeNewswire Inc.Esperion Announces Pricing of $85.1 Million Public Offering of Common StockNASDAQ:ESPREsperion Therapeutics Inc
      01/18/20244:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
      01/18/20244:01PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ESPREsperion Therapeutics Inc
      01/18/20244:00PMGlobeNewswire Inc.Esperion Announces Proposed Public Offering of Common StockNASDAQ:ESPREsperion Therapeutics Inc
      01/11/20244:09PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
      01/03/20243:15PMBusiness WireEsperion e Daiichi Sankyo Europe annunciano un emendamento da 125 milioni di dollari alla loro collaborazione, compresa la risoluzione di una controversia in corsoNASDAQ:ESPREsperion Therapeutics Inc
      01/03/20241:54PMBusiness WireEsperion et Daiichi Sankyo Europe annoncent une révision de leur collaboration pour un montant s’élevant à 125 millions USD, assortie de la résolution d’un litige en coursNASDAQ:ESPREsperion Therapeutics Inc
      01/03/202410:07AMBusiness WireEsperion und Daiichi Sankyo Europe geben Anpassung ihrer Zusammenarbeit in Höhe von 125 Millionen US-Dollar sowie die Beilegung eines anhängigen Rechtsstreits bekanntNASDAQ:ESPREsperion Therapeutics Inc
      01/03/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
      01/03/20247:00AMGlobeNewswire Inc.Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending LitigationNASDAQ:ESPREsperion Therapeutics Inc
      01/03/20247:00AMBusiness WireEsperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending LitigationNASDAQ:ESPREsperion Therapeutics Inc
      12/18/20238:00AMGlobeNewswire Inc.Esperion to Participate in 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
      12/13/20234:46PMDow Jones NewsEsperion Therapeutics' Nexletol, Nexlizet Updates Get FDA ApprovalNASDAQ:ESPREsperion Therapeutics Inc
      12/13/20234:00PMGlobeNewswire Inc.U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) TabletNASDAQ:ESPREsperion Therapeutics Inc
      11/13/202310:30AMGlobeNewswire Inc.Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023NASDAQ:ESPREsperion Therapeutics Inc
      11/11/202311:00AMGlobeNewswire Inc.Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023NASDAQ:ESPREsperion Therapeutics Inc
      11/09/20234:30PMGlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
      11/07/20238:52AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ESPREsperion Therapeutics Inc
      11/07/20237:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
      11/07/20236:00AMGlobeNewswire Inc.Esperion Reports Third Quarter 2023 Financial ResultsNASDAQ:ESPREsperion Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:ESPR

      Your Recent History

      BIT
      UC8FRA
      Unicredit Bank
      Delayed Upgrade Clock